The first flight of
a high-tech service company
Following several years based on the University of Auvergne campus, Aptys pharma® moved and took flight with the aim of becoming a high-tech service company with a performance-driven quality control system.
The company has continued to evolve by developing new skills, investing in a range of equipment and training, and recruiting qualified staff. Over the years, we have expanded our technological offer to include new areas of expertise and also in analytical development and drug quality control.
The phases of development
Since its inception in 2002, Aptys pharma® has been able to establish partnerships with pharmaceutical and biotechnology companies by licensing its patents or developing products based on customers’ specifications.
For example, in 2003, the firm sublicensed the BiGel® technology to the Scottish biotech, Ardana Biosciences. This agreement included the royalties if marketed and funding to develop an innovative formulation, Testocream®, a new transdermal form of testosterone.
And since 2004, Aptys pharma® has signed development contracts with many pharmaceutical companies such as Johnson & Johnson, Mylan, Nordic Pharma, Biogaran, Laboratoires Théa, Galderma, Servierand biotechnological companies such as Ardana, Advicenne, Neuronax, Alizé, Auris Medical, Antev, Viramal.
In 2005, Aptys pharma® licensed the Lauriad® technology to Bioalliance Pharma for the Loramyc® / Oravig® product, now marketed by Vectans Pharma.
determined progress inectricably
linked to our ambitions
Aptys pharma® actively participates in the development of the Analgesia Partnership pain cluster, better known today as the Analgesia Institute. And it was from within this cluster that Aptys pharma® launched the preclinical development of Metapain®, an innovative pain treatment that combines two non-opioid analgesics.
We then signed a co-development agreement with Unither Pharmaceuticals, an international CDMO, a world leader in BFS technology.
Group performance and development
The governance of Aptys pharma® is based on principles that contribute to maintaining the balance between performance and the proper development of the Group. It is ensured by a Strategy Committee, a Development Committee and an Executive Committee.
The role of the Strategy Committee is to support the management team in the development and evolution of its strategy, the analysis of its risks and opportunities, and relations with investors. The Development Committee’s is to support the management team in the development and marketing of the group’s products. The Management Committee is a forum for reflection, exchange and discussion on the challenges facing Aptys pharma® and monitors and steers the various activities.